Modality
siRNA
MOA
STINGag
Target
PCSK9
Pathway
Wnt
Cholangiocarcinoma
Development Pipeline
Preclinical
May 2021
→ Apr 2030
PreclinicalCurrent
NCT07331824
2,157 pts·Cholangiocarcinoma
2021-05→2030-04·Completed
2,157 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-114.0y awayInterim· Cholangiocarcinoma
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Complet…
Catalysts
Interim
2030-04-11 · 4.0y away
Cholangiocarcinoma
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07331824 | Preclinical | Cholangiocarcinoma | Completed | 2157 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |